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Pathological and biochemical investigation of a woman diagnosed with genetic 
Creutzfeldt-Jakob disease shortly after parturition 
 
Creutzfeldt-Jakob disease (CJD) is a rare fatal neurodegenerative condition that most 
commonly occurs in a sporadic form, predominantly in the elderly. Genetic and acquired 
forms of CJD also occur, and these may affect younger age groups, including women of 
childbearing age. The transmissible nature of CJD makes horizontal secondary transmission a 
concern generally; however a foetus born to a mother carrying a pathogenic mutation 
associated with CJD might be at risk of developing CJD as a result either of genetic 
inheritance or potential intrauterine exposure to infectivity. Here we report on the 
pathological investigation of a woman who developed a severe neuropsychiatric illness 
shortly after giving birth and who was diagnosed with genetic CJD.    
 
Human prion diseases are uniformly fatal neurodegenerative conditions that occur in 
idiopathic, acquired and genetic forms. All are transmissible, including the genetic forms, of 
which CJD E200K-129M is the most common [1]. There are analogous diseases in animals, 
such as scrapie in sheep and the epidemiology of scrapie suggests both horizontal and vertical 
transmission [2], but the exact mechanism of maternal transmission in scrapie is a matter of 
debate, with evidence for in utero exposure in addition to infection via the oral route around 
the time of birth [3]. 
The infectious agent in human and animal prion diseases is thought to be a misfolded and 
aggregated form of the prion protein (PrP) that undergoes a self-perpetuating conformational 
transition from the normal cellular isoform (PrPC) to the disease associated isoform (PrPSc) 
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that deposits in the brain and, in some prion diseases, at lower levels in peripheral tissues. 
The expression of PrPC within a tissue is therefore considered a precondition for both PrPSc 
accumulation and prion replication. The presence of PrPC in human blood [4] and human 
reproductive tissues, notably the placenta, has been documented [5,6] and is suggestive of a 
possible route of exposure. 
Evidence of vertical transmission in human prion disease is absent, but the evidence base is 
not large. A priori, variant CJD might be supposed to present the greatest risk of maternal 
transmission because of the younger age distribution of affected individuals, the disseminated 
nature of PrPSc and infectivity in peripheral tissues and the transmission of variant CJD 
infectivity by blood or blood products on five separate occasions 
(http://www.cjd.ed.ac.uk/TMER/TMER.htm). Despite the comparatively large numbers of 
parents with variant CJD known to the National CJD Research & Surveillance Unit, 
including nine women with clinical variant CJD while pregnant, no evidence of vertical 
transmission has been found, although further follow up was recommended considering the 
potentially lengthy incubation periods involved [7]. Nevertheless, it remains important to 
consider the possibility of secondary transmission in all forms of CJD, including the 
possibility of maternal transmission in the rare circumstances of a pregnancy in a person with 
clinical or pre-clinical CJD. 
The patient presented at the age of 32 years, after she gave birth at term with no 
complications. The baby subsequently showed developmental delay; investigations for a 
possible underlying metabolic disorder are being undertaken. The first symptoms were 
somewhat nonspecific comprising anxiety attacks, insomnia, psychotic symptoms and 
irritability during her pregnancy, which grew worse and resulted in admission to a psychiatric 
hospital. Before admission to the hospital she had experienced a seizure. Within weeks her 
state deteriorated: severe insomnia, cognitive decline and progressive gait imbalance was 
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observed; she was unable to communicate properly with the physicians, or to read. 
Myoclonic jerks were noted in all extremities. Cranial CT did not reveal atrophy or a space-
occupying lesion, however, cranial MRI performed one month after her admission revealed 
symmetric high signal intensity in the caudate nucleus and putamen.  EEG showed periodic 
sharp waves including those with a triphasic morphology. A search for neoplastic disease and 
paraneoplastic antibodies did not show positive results. Immunoblotting of the cerebrospinal 
fluid sample for protein 14-3-3 showed strong positivity (there was no blood contamination 
or elevated cell count), while genetic analysis of the PRNP revealed an E200K mutation and 
MM homozygosity at codon 129.  Further progression to akinetic mutism was observed and 
the patient died four months after the onset of clinical symptoms.  
Formalin fixed, paraffin-embedded tissue blocks were evaluated from several cortical areas; 
hippocampus, basal ganglia, thalamus, brainstem and cerebellum. In addition to 
Haematoxylin and Eosin, Luxol Fast Red, and Bielschowsky silver staining, the following 
monoclonal antibodies were used for immunohistochemistry: anti-PrP 3F4 (epitope: aa. 106-
112; 1:1,000, Signet/Covance, Berkeley, CA, USA), anti-PrP 12F10 (epitope: aa. 142-160; 
1:1,000, Cayman Chemical, Ann Arbor, MI, USA), anti-PrP 6H4 (epitope: aa. 144-152; 
1:500, Prionics, Schlieren, Switzerland), anti-tau AT8 (pS202/pT205, 1:200, Pierce 
Biotechnology, Rockford, IL, USA), anti-phospho-TDP-43 (pS409/410, 1:2,000, Cosmo Bio, 
Tokyo, Japan), anti-α-synuclein (1:2,000, clone 5G4, Roboscreen, Leipzig, Germany), anti-
Aβ (1:50, clone 6F/3D, Dako, Glostrup, Denmark), anti-p62 (1:1,000, BD Transduction, 
Lexington KY, USA), The DAKO EnVision© detection kit, peroxidase/DAB, rabbit/mouse 
(Dako, Glostrup, Denmark) was used for visualization of antibody reactions. In addition the 
internal organs (spleen, heart, skeletal muscle, liver, lung, kidney, uterus and ovary) were also 
immunostained for PrP. The most striking alteration was the presence of spongiform change 
in the neuropil, which was accentuated in the deeper layers of the cortex. This was associated 
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with an unusually high degree of neuronal loss and gemistocytic type of reactive astrogliosis 
in all examined neocortical areas (Figure 1A). Importantly, the CA subregions of the 
hippocampus and the brainstem nuclei were relatively preserved. The thalamus and the basal 
ganglia showed reactive gliosis and neuronal loss but only moderate or mild spongiform 
change. The cerebellar molecular layer showed only mild spongiform degeneration, however 
there was loss of Purkinje cells with Bergmann gliosis (Figure 1B). The severe degree of 
cortical and subcortical reactive astrogliosis and neuronal loss was somewhat unusual as 
compared to other E200K patients from Hungary.  Immunostaining for PrP showed 
diffuse/synaptic immunoreactivity in all examined regions (Figure 1C), without neuronal, 
perineuronal or perivacuolar accentuation. There was lack of kuru type plaques, florid 
plaques or PrP plaques. We observed diffuse PrP immunoreactivity in the cerebellar cortex 
(Figure 1D), but not the stripe-like pattern, which is seen frequently, at least in the cohort of 
Hungarian patients [1]. The internal organs did not show PrP immunostaining. In addition, 
there was a lack of depositions of different neurodegenerative disease-related proteins, which 
often concur with the E200K mutation [1].  
Frozen tissue specimens were available from the brain, spleen, heart, skeletal muscle, liver, 
lung, kidney, uterus and ovary. Western blot analysis for protease-resistant (disease 
associated) prion protein (PrPres) showed readily detectable PrPres in the cerebral cortex 
(frontal lobe) and in the cerebellum (Figure 2A,B). The electrophoretic mobility of the non-
glycosylated PrPres (lowest band) was around 21kDa and had the same electrophoretic 
mobility as type 1 in a reference case of sporadic CJD of the MM1 subtype. The ratio of the 
three glycoforms in both frontal cortex and cerebellum in this case was dominated by the 
upper two (mono- and di-glycosylated) forms and was intermediate in ratio between the 
sporadic CJD (type 1A) and variant CJD (type 2B) reference standards. The pattern is 
classified by us as type 1A/B, and it is typical of genetic CJD associated with the E200K-
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129M [1,8]. Sodium phosphotungstic acid (NaPTA) precipitation in advance of Western 
blotting was used to enrich for PrPSc from larger volumes of tissue homogenates of peripheral 
tissues from this case to determine whether PrPres is present at levels lower than those found 
in the brain. Recovery of brain PrPres from this case spiked into non-CJD brain and non-CJD 
spleen homogenate was found to be efficient and functions as a positive control for NaPTA 
precipitation and Western blotting. However, no specific signal denoting the presence of 
PrPres was observed in samples of heart, skeletal muscle, spleen, liver, lung, kidney, uterus or 
ovary from this case (Figure 2C,D) suggesting that if PrPSc (and by implication prion 
infectivity) is present in these tissues it must be present only at very low levels.  
To our knowledge this report constitutes the first detailed pathological investigation of a 
patient with genetic CJD who developed severe neuropsychiatric symptoms shortly after the 
birth of a child. All of the available clinical, genetic, pathological and biochemical data 
indicate that this patient had CJD typical of that associated with the E200K-129M haplotype 
[1]. The absence of detectable PrPres in peripheral tissues is consistent with pathological 
changes originating in the brain with only limited centrifugal spread to the periphery (as is 
found in sporadic CJD), compared to variant CJD in which there is clear evidence of 
peripheral nervous and lymphoreticular tissue involvement [9,10]. The situation pertaining to 
ovary and uterus bear further comment: PrPres has been demonstrated in uterus and ovary in a 
patient with variant CJD who was not pregnant whilst ill [11], whereas no evidence could be 
found of the presence of PrPres in the uterus, placenta or amniotic fluid from a gravida with 
sporadic CJD of the VV1 subtype [12]. Taken together these data and ours indicate that in 
genetic CJD (of at least the E200K type) the involvement of the female reproductive tract 
more closely resembles that of sporadic rather than variant CJD. Although this may offer the 
foetus a degree of protection from intrauterine exposure, it does not obviate the genetic risk.  
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Figure legends  
Figure 1. Histopathology of the reported case. A: Severe astrogliosis in the frontal cortex 
(x400). B: Mild spongiform change in the cerebellar molecular layer and loss of Purkinje 
cells with Bergmann gliosis (x400). C: Diffuse/synaptic PrP immunoreactivity (12F10) in the 
frontal cortex (x200). D: Diffuse/synaptic immunroeactivity in the cerebellar cortex (12F10) 
(x200). 
Figure 2. Biochemical investigation of the reported case. Conventional diagnostic Western 
blot analysis of frontal cortex (A) and cerebellum (B) 10% w/v brain homogenate, loaded as 
5ul without proteinase K digestion (-), or as 0.5ul (0.5), 5ul (5), or 50ul collected by 
centrifugation ([50]) after proteinase K digestion.  Molecular mass standards (M) and ~5ul of 
10% w/v proteinase K digested frontal cortex from sCJD MM1 subtype (1A), sCJD VV2A 
subtype (2A) and vCJD (2B) are shown for reference. (C,D) shows NaPTA precipitation, 
proteinase K digestion and Western blot analysis of 500ul of 10% w/v homogenates [500 
NaPTA]  of heart (H), muscle (M) and spleen (S), liver (Li), lung (Lu), kidney (K), uterus (U) 
and ovary (O). For NaPTA Western blot analysis additional controls were performed in 
which 500ul of negative brain (B-) and 500ul of negative spleen (S-) homogenates were 
spiked with 5ul of 10% w/v frontal cortex homogenate from this case (B+) and (S+) 
respectively, prior to NaPTA precipitation, proteinase K digestion and Western blot analysis. 
Lanes marked above the figure show analysis of samples from the case in question, whereas 
those marked below show the analysis of reference standards. 
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